Current Report Filing (8-k)
15 Décembre 2017 - 6:57PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
December 12, 2017
PhaseRx, Inc.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
001-37772
|
|
20-4690620
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
410 W. Harrison Street, Suite 300
Seattle, Washington
|
|
98119
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code:
(206) 805-6300
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
|
As previously disclosed, on December 11,
2017, PhaseRx, Inc. (the “Company”) filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the
U.S. Bankruptcy Court for the District of Delaware (the “Chapter 11 Case”).
On December 12, 2017, the Company received
a letter from the Listing Qualifications Department of the Nasdaq Stock Market (the “Staff”) notifying the Company
that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company’s filing
of the Chapter 11 Case serves as an additional basis for delisting the Company’s common stock from Nasdaq. The letter also
notified the Company that the Nasdaq Hearings Panel (the “Panel”) will consider this additional basis for delisting
in its decision regarding the Company’s continued listing on The Nasdaq Capital Market, and in that regard, the Company should
present its views with respect to this additional deficiency to the Panel in writing no later than December 19, 2017. At the hearing
before the Panel held on December 7, 2017, the Company had discussed the possibility of a bankruptcy filing, and the Panel factored
the bankruptcy filing and related considerations into the terms of conditional listing set forth below under Item 8.01. The Company
intends to make every effort to satisfy the terms of the Panel’s conditional listing, though it can provide no assurances
that it will be able to do so. The Company intends to communicate the foregoing to the Panel prior to December 19, 2017.
|
Item 8.01
|
Other Events. (Update of Information Previously Reported
Under Item 3.01)
|
The Company previously disclosed that on
August 22, 2017, it received a letter from the Staff indicating that the Company no longer complies with the minimum $2.5 million
stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market.
On September 21, 2017, the Company submitted a plan of compliance, which was rejected by the Staff. On October 30, 2017, the Company
requested a hearing to appeal the Staff’s determination, which was held on December 7, 2017.
On December 12, 2017, the Company received
a decision letter from Nasdaq notifying the Company that the Panel has determined to grant the Company’s request for continued
listing of the Company’s common stock subject to the conditions that the Company shall have completed a Section 363 auction
process pursuant to Chapter 11 of Title 11 of the U.S. Bankruptcy Code by January 31, 2018, at which time the Company’s common
stock will be delisted from Nasdaq. In the event the Company is unable to meet these conditions, the Company’s common stock
may be delisted from Nasdaq. There can be no assurance the Company will be able to meet these conditions or be able to maintain
its listing on Nasdaq. In addition, the Panel’s appellate body, the Nasdaq Listing and Hearing Review Council, may, on its
own motion, determine to review the Panel’s decision within 45 calendar days after issuance of the written decision, and
may affirm, modify, reverse, dismiss or remand the decision to the Panel.
On December 13, 2017, the Company issued
a press release announcing the Panel’s determination. A copy of this press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PhaseRx, Inc.
|
|
|
|
Date: December 15, 2017
|
By:
|
/s/ Robert W. Overell
|
|
|
Robert W. Overell, Ph.D.
|
|
|
Chief Executive Officer
|
PhaseRx (CE) (USOTC:PZRXQ)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
PhaseRx (CE) (USOTC:PZRXQ)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about PhaseRx Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Phaserx, Inc.